T1	PROC 44 64	Estudio de fase 3b/4
T2	DISO 68 87	artritis reumatoide
#1	AnnotatorNotes T2	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T3	PROC 109 204	Estudio de fase 3b/4, aleatorizado, comparativo con un tratamiento activo, con grupos paralelos
T5	CHEM 226 237	baricitinib
#2	AnnotatorNotes T5	C4044947; baricitinib; Organic Chemical · Pharmacologic Substance
T6	DISO 255 274	artritis reumatoide
#3	AnnotatorNotes T6	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T7	DISO 298 317	Artritis reumatoide
#4	AnnotatorNotes T7	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T8	CHEM 434 517	fármaco antirreumático modificador de la enfermedad (FARME) (sintético o biológico)
#5	AnnotatorNotes T8	C4055380; Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance | C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
T9	DISO 600 606	signos
#6	AnnotatorNotes T9	C0311392; Physical findings; Finding
T10	DISO 623 626	TEV
#7	AnnotatorNotes T10	C1861172; Venous Thromboembolism; Disease or Syndrome
T11	PROC 703 706	IMC
#8	AnnotatorNotes T11	C0005893; Body mass index procedure; Diagnostic Procedure | C3698309; Measurement of body mass index; Health Care Activity
T12	PROC 817 820	IMC
#9	AnnotatorNotes T12	C0005893; Body mass index procedure; Diagnostic Procedure | C3698309; Measurement of body mass index; Health Care Activity
T13	CHEM 940 982	inhibidores del factor de necrosis tumoral
T14	CHEM 990 1001	baricitinib
#10	AnnotatorNotes T14	C4044947; baricitinib; Organic Chemical · Pharmacologic Substance
T15	CHEM 984 987	TNF
#11	AnnotatorNotes T15	C1456820; Tumor Necrosis Factor-alpha; Amino Acid, Peptide, or Protein · Immunologic Factor
T16	CHEM 1041 1051	excipiente
#12	AnnotatorNotes T16	C0015237; Pharmaceutical Excipient; Biomedical or Dental Material
T17	DISO 1270 1276	cáncer
#13	AnnotatorNotes T17	C0006826; Malignant Neoplasms; Neoplastic Process
T18	DISO 1228 1231	TEV
#14	AnnotatorNotes T18	C1861172; Venous Thromboembolism; Disease or Syndrome
T19	DISO 1313 1326	herpes zóster
#15	AnnotatorNotes T19	C0019360; Herpes zoster disease; Disease or Syndrome
T20	DISO 1335 1346	infecciones
#16	AnnotatorNotes T20	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T21	DISO 1355 1367	tuberculosis
#17	AnnotatorNotes T21	C0041296; Tuberculosis; Disease or Syndrome
T22	DISO 1393 1403	enfermedad
#18	AnnotatorNotes T22	C0012634; Disease; Disease or Syndrome
T23	DISO 1466 1483	infección por VIH
#19	AnnotatorNotes T23	C0019693; HIV Infections; Disease or Syndrome
T24	PROC 1512 1532	anticuerpos anti-VIH
#20	AnnotatorNotes T24	C0373916; HIV-1 Antibody Measurement; Laboratory Procedure
T25	PROC 1747 1761	ensayo clínico
#21	AnnotatorNotes T25	C0008976; Clinical Trials; Research Activity
T26	PROC 1817 1831	aleatorización
#22	AnnotatorNotes T26	C0034656; Randomization; Research Activity
T27	DISO 1896 1915	alcoholismo crónico
#23	AnnotatorNotes T27	C0001973; Alcoholic Intoxication, Chronic; Mental or Behavioral Dysfunction
T28	DISO 1917 1929	drogadicción
#24	AnnotatorNotes T28	C1510472; Drug Dependence; Mental or Behavioral Dysfunction
T29	CHEM 1931 1937	drogas
#25	AnnotatorNotes T29	C0086190; Illicit Drugs; Hazardous or Poisonous Substance
T30	DISO 1959 1970	toxicomanía
#26	AnnotatorNotes T30	C1510472; Drug Dependence; Mental or Behavioral Dysfunction
T31	DISO 407 419	intolerancia
#27	AnnotatorNotes T31	C0277585; Intolerance to drug; Pathologic Function
T32	PROC 678 701	índice de masa corporal
#28	AnnotatorNotes T32	C0005893; Body mass index procedure; Diagnostic Procedure | C3698309; Measurement of body mass index; Health Care Activity
T33	ANAT 693 701	corporal
#29	AnnotatorNotes T33	C0460148; Human body structure; Anatomical Structure | C1318419; Entire human body; Anatomical Structure
T34	CHEM 1006 1022	sustancia activa
T35	CHEM 1582 1618	vacuna elaborada con microbios vivos
T36	Date 12 16	2018
T37	LIVB 241 250	pacientes
#30	AnnotatorNotes T37	C0030705; Patients; Patient or Disabled Group
T38	LIVB 523 532	pacientes
#31	AnnotatorNotes T38	C0030705; Patients; Patient or Disabled Group
T39	Age 652 674	edad mínima de 60 años
T41	Age 779 811	entre 50 años y menos de 60 años
T42	LIVB 886 899	participantes
#32	AnnotatorNotes T42	C4554048; Study Participant; Population Group
T44	Neg_cue 1108 1110	no
T45	Neg_cue 1135 1137	ni
T47	Neg_cue 1253 1255	no
T48	LIVB 1284 1293	pacientes
#33	AnnotatorNotes T48	C0030705; Patients; Patient or Disabled Group
T49	Neg_cue 1294 1296	no
T50	Neg_cue 1375 1377	ni
T51	LIVB 1439 1448	pacientes
#34	AnnotatorNotes T51	C0030705; Patients; Patient or Disabled Group
T52	Neg_cue 1554 1556	no
T53	LIVB 1603 1612	microbios
#35	AnnotatorNotes T53	C0445623; Microorganism; Organism
T54	Duration 1639 1657	las cuatro semanas
T55	Neg_cue 1712 1714	no
T56	Duration 1782 1800	las cuatro semanas
T57	Neg_cue 1865 1867	no
T58	Duration 1908 1915	crónico
#36	AnnotatorNotes T58	C0205191; chronic; Temporal Concept
T59	Route 1938 1950	intravenosas
#37	AnnotatorNotes T59	C1522726; Intravenous Route of Drug Administration; Functional Concept
T60	Duration 1999 2009	último año
T62	PHYS 1123 1134	embarazadas
#38	AnnotatorNotes T62	C0032961; Pregnancy; Organism Function
T63	LIVB 1480 1483	VIH
#39	AnnotatorNotes T63	C0019682; HIV; Virus
T64	LIVB 1529 1532	VIH
#40	AnnotatorNotes T64	C0019682; HIV; Virus
T65	LIVB 348 361	participantes
#41	AnnotatorNotes T65	C4554048; Study Participant; Population Group
T40	PHYS 1152 1161	lactancia
#42	AnnotatorNotes T40	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T43	DISO 475 485	enfermedad
#43	AnnotatorNotes T43	C0012634; Disease; Disease or Syndrome
T46	LIVB 1094 1107	participantes
#44	AnnotatorNotes T46	C4554048; Study Participant; Population Group
T61	LIVB 1169 1182	participantes
#45	AnnotatorNotes T61	C4554048; Study Participant; Population Group
T66	LIVB 1239 1252	participantes
#46	AnnotatorNotes T66	C4554048; Study Participant; Population Group
T67	LIVB 1851 1864	participantes
#47	AnnotatorNotes T67	C4554048; Study Participant; Population Group
T68	LIVB 1698 1711	participantes
#48	AnnotatorNotes T68	C4554048; Study Participant; Population Group
T69	LIVB 1540 1553	participantes
#49	AnnotatorNotes T69	C4554048; Study Participant; Population Group
A1	Assertion T27 Negated
A2	Assertion T28 Negated
A3	Assertion T30 Negated
A4	Assertion T29 Negated
A5	Assertion T62 Negated
A6	Assertion T40 Negated
A7	Assertion T17 Negated
A8	Assertion T19 Negated
A9	Assertion T20 Negated
A10	Assertion T21 Negated
A11	Assertion T22 Negated
A12	Assertion T35 Negated
A13	Assertion T25 Negated
A14	Status T25 History_of
A15	Status T35 History_of
A16	Status T27 History_of
A17	Status T28 History_of
A18	Status T29 History_of
A19	Status T30 History_of
A20	Status T18 History_of
A21	Status T10 History_of
#50	AnnotatorNotes T13	C3537192; Tumor Necrosis Factor Inhibitors; Pharmacologic Substance 
#51	AnnotatorNotes T1	C1706097; Trial Phase 3B; Research Activity + C0282462; Phase 4 Clinical Trials; Research Activity
T4	Observation 922 930	problema
A22	Assertion T4 Negated
#52	AnnotatorNotes T4	C1301624; Medical contraindication; Finding (?)
T70	Neg_cue 915 921	ningún
R1	Negation Arg1:T70 Arg2:T4	
R2	Causes Arg1:T13 Arg2:T4	
R3	Causes Arg1:T15 Arg2:T4	
R4	Causes Arg1:T14 Arg2:T4	
R5	Causes Arg1:T34 Arg2:T4	
R6	Causes Arg1:T16 Arg2:T4	
R7	Negation Arg1:T44 Arg2:T62	
R8	Negation Arg1:T45 Arg2:T40	
T71	Neg_cue 1183 1185	no
T72	Quantifier_or_Qualifier 1206 1224	más de un episodio
A23	Assertion T72 Negated
R9	Negation Arg1:T71 Arg2:T72	
R10	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T72	
R11	Negation Arg1:T47 Arg2:T17	
R12	Negation Arg1:T49 Arg2:T19	
T73	Quantifier_or_Qualifier 1327 1333	activo
A24	Assertion T73 Negated
#53	AnnotatorNotes T73	C0679217; Active State; Idea or Concept
R13	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T73	
T74	Quantifier_or_Qualifier 1347 1353	graves
A25	Assertion T74 Negated
#54	AnnotatorNotes T74	C1547227; Severe - Severity of Illness Code; Intellectual Product
R14	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T74	
R15	Negation Arg1:T49 Arg2:T20	
R16	Negation Arg1:T49 Arg2:T73	
R17	Negation Arg1:T49 Arg2:T74	
T75	Quantifier_or_Qualifier 1368 1374	activa
A26	Assertion T75 Negated
#55	AnnotatorNotes T75	C0679217; Active State; Idea or Concept
R18	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T75	
R19	Negation Arg1:T49 Arg2:T75	
R20	Negation Arg1:T49 Arg2:T21	
R21	Negation Arg1:T50 Arg2:T22	
T76	Quantifier_or_Qualifier 1404 1409	grave
A27	Assertion T76 Negated
#56	AnnotatorNotes T76	C1547227; Severe - Severity of Illness Code; Intellectual Product
R22	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T76	
R23	Negation Arg1:T50 Arg2:T76	
R24	Negation Arg1:T52 Arg2:T35	
R25	Negation Arg1:T55 Arg2:T25	
T77	Quantifier_or_Qualifier 1742 1746	otro
A28	Assertion T77 Negated
R26	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T77	
R27	Negation Arg1:T55 Arg2:T77	
R28	Negation Arg1:T57 Arg2:T27	
R29	Negation Arg1:T57 Arg2:T28	
R30	Negation Arg1:T57 Arg2:T29	
A29	Assertion T59 Negated
R31	Negation Arg1:T57 Arg2:T59	
R32	Has_Route_or_Mode Arg1:T29 Arg2:T59	
R33	Negation Arg1:T57 Arg2:T30	
R34	Experiences Arg1:T37 Arg2:T5	
R35	Experiences Arg1:T37 Arg2:T6	
R36	Experiences Arg1:T65 Arg2:T31	
R37	Causes Arg1:T8 Arg2:T31	
R38	Experiences Arg1:T65 Arg2:T43	
T78	Observation 382 404	respuesta insuficiente
#57	AnnotatorNotes T78	C1320680; Poor response to treatment; Finding
R39	Experiences Arg1:T65 Arg2:T78	
R40	Overlap Arg1:T78 Arg2:T8	
R41	Causes Arg1:T10 Arg2:T9	
T79	PROC 641 648	estudio
#58	AnnotatorNotes T79	C0008976; Clinical Trials; Research Activity
R42	Before Arg1:T9 Arg2:T79	
A30	Status T9 History_of
R43	Location_of Arg1:T33 Arg2:T32	
R44	Location_of Arg1:T33 Arg2:T11	
T80	Result_or_Value 708 765	igual o mayor de 30 kilogramos por metro cuadrado (kg/m2)
R45	Has_Result_or_Value Arg1:T32 Arg2:T80	
R46	Has_Result_or_Value Arg1:T11 Arg2:T80	
T81	Result_or_Value 824 852	entre 25 y menos de 30 kg/m2
R47	Has_Result_or_Value Arg1:T12 Arg2:T81	
R48	Overlap Arg1:T12 Arg2:T41	
R49	Experiences Arg1:T42 Arg2:T4	
#59	AnnotatorNotes T34	C0574031; Biologically Active Substance; Biologically Active Substance (?)
R50	Experiences Arg1:T46 Arg2:T62	
R51	Experiences Arg1:T46 Arg2:T40	
R52	Experiences Arg1:T61 Arg2:T18	
R53	Experiences Arg1:T66 Arg2:T17	
R54	Experiences Arg1:T48 Arg2:T19	
R55	Experiences Arg1:T48 Arg2:T20	
R56	Experiences Arg1:T48 Arg2:T21	
R57	Experiences Arg1:T48 Arg2:T22	
R58	Experiences Arg1:T51 Arg2:T23	
R59	Causes Arg1:T63 Arg2:T23	
A31	Assertion T23 Negated
A32	Assertion T24 Negated
T82	Result_or_Value 1497 1506	positivos
A33	Assertion T82 Negated
#60	AnnotatorNotes T82	C1446409; Positive; Finding
R60	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T82	
R61	Experiences Arg1:T51 Arg2:T24	
R62	Causes Arg1:T64 Arg2:T82	
R63	Causes Arg1:T63 Arg2:T82	
R64	Experiences Arg1:T69 Arg2:T35	
R65	Overlap Arg1:T35 Arg2:T54	
T83	CONC 1672 1690	inicio del estudio
#61	AnnotatorNotes T83	C4684789; Study Start; Temporal Concept | C2349982; Study start time; Temporal Concept
R66	Before Arg1:T35 Arg2:T83	
#62	AnnotatorNotes T35	C0042211; Vaccines, Attenuated; Pharmacologic Substance · Immunologic Factor
R67	Overlap Arg1:T25 Arg2:T56	
R68	Before Arg1:T25 Arg2:T26	
R69	Experiences Arg1:T67 Arg2:T27	
R70	Has_Duration_or_Interval Arg1:T27 Arg2:T58	
R71	Experiences Arg1:T67 Arg2:T28	
R72	Experiences Arg1:T67 Arg2:T29	
R73	Causes Arg1:T29 Arg2:T28	
R74	Experiences Arg1:T67 Arg2:T30	
R75	Overlap Arg1:T30 Arg2:T60	
R76	Overlap Arg1:T28 Arg2:T60	
R77	Overlap Arg1:T29 Arg2:T60	
R78	Overlap Arg1:T27 Arg2:T60	
T84	Quantifier_or_Qualifier 420 433	al menos a un
R79	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T84	
R80	Experiences Arg1:T42 Arg2:T13	
R81	Experiences Arg1:T42 Arg2:T15	
R82	Experiences Arg1:T42 Arg2:T14	
R83	Experiences Arg1:T42 Arg2:T34	
R84	Experiences Arg1:T42 Arg2:T16	
#63	AnnotatorNotes T77	C0205394; Other; Qualitative Concept
A34	Experiencer T37 Patient
A35	Experiencer T65 Patient
A36	Experiencer T38 Patient
A37	Experiencer T42 Patient
A38	Experiencer T46 Patient
A39	Experiencer T61 Patient
A40	Experiencer T66 Patient
A41	Experiencer T48 Patient
A42	Experiencer T51 Patient
A43	Experiencer T69 Patient
A44	Experiencer T68 Patient
A45	Experiencer T67 Patient
